Pre-exposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF), can effectively prevent HIV acquisition. However, TDF can cause changes in bone mineral density (BMD). There is little information on the use of PrEP among patients with bone disease. We present a case report of a female with pre-existing osteoporosis who was prescribed PrEP. Over the course of 9 months of consistent PrEP use, verified by dried blood spot testing, we report a lack of BMD changes on serial dual-emission X-ray absorptiometry scans in this patient. This case can inform PrEP care for patients with pre-existing bone disease.

中文翻译：

---

替诺福韦富马酸替诺福韦酯预防骨质疏松症妇女的HIV暴露前预防：一例病例并文献复习。

使用替诺福韦富马酸替诺福韦酯（TDF）进行暴露前预防（PrEP）可有效预防HIV感染。但是，TDF会引起骨矿物质密度（BMD）的变化。在骨病患者中使用PrEP的信息很少。我们介绍了一名女性患者，该患者患有预先存在的骨质疏松症，处方了PrEP。在经过连续9个月的PrEP持续使用的过程中（通过干血斑测试验证），我们报告了该患者在连续双发射X射线吸收仪扫描中缺乏BMD变化。这种情况可以告知PrEP对已有骨病患者的护理。